Saturday, October 25

Syndax Prescribed drugs, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia – Slideshow

$Syndax Prescribed drugs, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia – Slideshow$

Holcim AG (HCMLY) Q3 2025 Gross sales Name Transcript